Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval

Open access
Yousaf-Khan, Uraujh, van der Aalst, Carlijn, de Jong, Pim A, Heuvelmans, Marjolein, Scholten, Ernst, Lammers, Jan-Willem, van Ooijen, Peter, Nackaerts, Kristiaan, Weenink, Carla, Groen, Harry, Vliegenthart, Rozemarijn, ten Haaf, Kevin, Oudkerk, Matthijs, de Koning, Harry·2017·Thorax

Abstract

BACKGROUND: In the USA annual lung cancer screening is recommended. However, the optimal screening strategy (eg, screening interval, screening rounds) is unknown. This study provides results of the fourth screening round after a 2.5-year interval in the Dutch-Belgian Lung Cancer Screening trial (NELSON). METHODS: Europe's largest, sufficiently powered randomised lung cancer screening trial was designed to determine whether low-dose CT screening reduces lung cancer mortality by ≥25% compared with no screening after 10 years of follow-up. The screening arm (n=7915) received screening at baseline, after 1 year, 2 years and 2.5 years. Performance of the NELSON screening strategy in the final fourth round was evaluated. Comparisons were made between lung cancers detected in the first three rounds, in the final round and during the 2.5-year interval. RESULTS: In round 4, 46 cancers were screen-detected and there were 28 interval cancers between the third and fourth screenings. Compared with the second round screening (1-year interval), in round 4 a higher proportion of stage IIIb/IV cancers (17.3% vs 6.8%, p=0.02) and higher proportions of squamous-cell, bronchoalveolar and small-cell carcinomas (p=0.001) were detected. Compared with a 2-year interval, the 2.5-year interval showed a higher non-significant stage distribution (stage IIIb/IV 17.3% vs 5.2%, p=0.10). Additionally, more interval cancers manifested in the 2.5-year interval than in the intervals of previous rounds (28 vs 5 and 28 vs 19). CONCLUSIONS: A 2.5-year interval reduced the effect of screening: the interval cancer rate was higher compared with the 1-year and 2-year intervals, and proportion of advanced disease stage in the final round was higher compared with the previous rounds. TRIAL REGISTRATION NUMBER: ISRCTN63545820.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thoraxjnl-2016-208655

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 263

Metadata

Authors
Yousaf-Khan, U., van der Aalst, C., de Jong, P. A., Heuvelmans, M., Scholten, E., Lammers, J.-W., van Ooijen, P., Nackaerts, K., Weenink, C., Groen, H., Vliegenthart, R., ten Haaf, K., Oudkerk, M., & de Koning, H.
Venue
Thorax
Publisher
BMJ
Published
2016-06-30
Volume
72
Issue
1
Pages
48-56
ISSN
  • 0040-6376 (ISSN-L)
  • 1468-3296
OpenAlex
W2474121040
Cited by
263
References
21
FWCI
24.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. https://app.cochat.ai/papers/10.1136/thoraxjnl-2016-208655
The paper
Yousaf-Khan, U., van der Aalst, C., de Jong, P. A., Heuvelmans, M., Scholten, E., Lammers, J.-W., van Ooijen, P., Nackaerts, K., Weenink, C., Groen, H., Vliegenthart, R., ten Haaf, K., Oudkerk, M., & de Koning, H. (2017). Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. https://doi.org/10.1136/thoraxjnl-2016-208655

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.